Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo Combi: Neoadjuvant Dabrafenib + Trametinib in Stage IIIB-C Melanoma
NCT01972347Phase 2Completed
- Sponsor
- Melanoma Institute Australia
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by Melanoma Institute Australia. Started Oct 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01972347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972347.